The big biosimilar opportunity, according to Morgan Stanley

Apr 18, 2019, 05:30 AM

Themedicinebox podcast gives you vital insights on all things pharma and health — from discussing trends in the industry to key issues in health with all the relevant experts.

The third series focuses on the top sell-side analysts covering the pharma and healthcare sector. They share their views on the big emerging trends, the big growth markets, R&D and more.

In the first episode, Sameer Baisiwala, executive director and senior analyst at Morgan Stanley, shares details about the global investment firm's latest global insight report on biosimilars– Infancy to Youth.

What are the opportunities and threats to the global biosimilar market? Morgan Stanley believes the US and EU biosimilar markets will grow nearly 10 times to $13.3 billion by 2025 from 2018, a 24 percent CAGR. Where does India figure in the biosimilar opportunity?

Jump right in!